These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28817831)

  • 1. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study.
    Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V
    Nephron; 2017; 137(3):205-211. PubMed ID: 28817831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis.
    Wong SS; Lau WY; Chan PK; Wan CK; Cheng YL
    Nephrology (Carlton); 2017 Nov; 22(11):921-924. PubMed ID: 28767200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
    Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
    Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
    Verhave G; Weijmer MC; van Jaarsveld BC
    Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin in hemodialysis patients with a bleeding tendency.
    Leu JG; Chiang SS; Lin SM; Pai JK; Jiang WW
    Nephron; 2000 Dec; 86(4):499-501. PubMed ID: 11124600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin.
    Pauwels R; Devreese K; Van Biesen W; Eloot S; Glorieux G; Vanholder R; Dhondt A
    Nephrol Dial Transplant; 2014 May; 29(5):1092-6. PubMed ID: 24366900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
    Oudemans-van Straaten HM; van Schilfgaarde M; Molenaar PJ; Wester JP; Leyte A
    Crit Care; 2009; 13(6):R193. PubMed ID: 19958532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
    Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
    Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of low-dose low molecular weight heparin in hemodialysis.
    Lai KN; Wang AY; Ho K; Szeto CC; Li M; Wong LK; Yu AW
    Am J Kidney Dis; 1996 Nov; 28(5):721-6. PubMed ID: 9158210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels.
    Olie RH; Meertens NEL; Henskens YMC; Ten Cate H
    Nephron; 2017; 137(2):113-123. PubMed ID: 28662505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
    Reach I; Luong N; Chastang C; Chakroun M; Mirshahi S; Mirshahi MC; Soria J; Desmichels D; Baumelou A
    Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.
    Christidou FN; Frangia TK; Bamichas GI; Gionanlis LC; Natse TA; Georgoulis IE; Sombolos KI
    Int J Clin Pharmacol Ther; 2005 Jul; 43(7):335-8. PubMed ID: 16035376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.
    Guillet B; Simon N; Sampol JJ; Lorec-Penet AM; Portugal H; Berland Y; Dussol B; Brunet P
    Nephrol Dial Transplant; 2003 Nov; 18(11):2348-53. PubMed ID: 14551364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ; Wang L
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.